¼¼°èÀÇ »ïÁßÀ½¼ºÀ¯¹æ¾Ï Ä¡·á ½ÃÀå
Triple Negative Breast Cancer Treatment
»óǰÄÚµå : 1795183
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 285 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,218,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,655,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

»ïÁßÀ½¼ºÀ¯¹æ¾Ï Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 14¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 10¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â »ïÁßÀ½¼ºÀ¯¹æ¾Ï Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 14¾ï ´Þ·¯¿¡ ´ÞÇϰí, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 4.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ µ¶¼Ò·çºñ½Å ÀǾàǰÀº CAGR 5.8%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 3¾ï 8,470¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »çÀÌŬ·ÎÆ÷½ºÆÄ¹Ìµå ÀǾàǰ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 2¾ï 8,240¸¸ ´Þ·¯, Áß±¹Àº CAGR 8.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ »ïÁßÀ½¼ºÀ¯¹æ¾Ï Ä¡·á ½ÃÀåÀº 2024³â¿¡ 2¾ï 8,240¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2024³âºÎÅÍ 2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 8.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 2¾ï 8,300¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.8%¿Í 3.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ »ïÁßÀ½¼ºÀ¯¹æ¾Ï Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

»ïÁßÀ½¼º À¯¹æ¾ÏÀ» º¹ÀâÇÏ°í ±ä±ÞÇÏ°Ô Ä¡·áÇØ¾ß ÇÏ´Â ÀÌÀ¯´Â?

»ïÁßÀ½¼ºÀ¯¹æ¾Ï(TNBC)Àº Ç¥ÁØ À¯¹æ¾Ï Ä¡·á¿¡¼­ Ç¥ÀûÀ¸·Î »ï´Â ¼¼ °¡Áö ÁÖ¿ä ¼ö¿ëü(¿¡½ºÆ®·Î°Õ, ÇÁ·Î°Ô½ºÅ×·Ð, HER2)°¡ °á¿©µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ ¼ö¿ëüÀÇ °á¿©·Î ÀÎÇØ TNBC´Â ¸Å¿ì °ø°ÝÀûÀ̾ È­Çпä¹ýÀ» Áß½ÉÀ¸·Î ÇÑ Ä¡·á ¿É¼ÇÀÌ Á¦ÇÑÀûÀÔ´Ï´Ù. ÀÌ Áúº´Àº ÀþÀº ¿©¼º¿¡°Ô ¹ßº´ÇÏ´Â °æÇâÀÌ ÀÖÀ¸¸ç, ¾ÆÇÁ¸®Ä«Àΰú È÷½ºÆÐ´Ð°è »ç¶÷µé¿¡°Ô¼­ ºÒ±ÕÇüÀûÀ¸·Î ¹ß»ýÇÕ´Ï´Ù. ³ôÀº Àç¹ß·ü°ú ÀüÀÌÀ²Àº ÀÓ»óÀû °á°ú¸¦ ´õ¿í º¹ÀâÇÏ°Ô ¸¸µé°í ÀÖÀ¸¸ç, »õ·Î¿î Ä¡·á ¿É¼ÇÀ» ã´Â °ÍÀÌ Áß¿äÇÑ ÀÇÇÐÀû ¿ì¼±¼øÀ§°¡ µÇ°í ÀÖ½À´Ï´Ù.

TNBC´Â ¶ÇÇÑ »ó´çÇÑ ºÐÀÚ ºÒ±ÕÀϼºÀ» ³ªÅ¸³À´Ï´Ù. ¿¬±¸ÀÚµéÀº ´Ù¾çÇÑ À¯ÀüÀû ¹× ÈÄ»ýÀ¯ÀüÇÐÀû ¾ÆÇüÀ» ¹àÇô³»°í ÀÖÀ¸¸ç, ÀÌ´Â º¸´Ù °³ÀÎÈ­µÈ ¹ÙÀÌ¿À¸¶Ä¿ Áß½ÉÀÇ Ä¡·á Á¢±Ù¹ýÀ¸·ÎÀÇ ÀüȯÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸íÈ®ÇÑ µ¹¿¬º¯ÀÌ ÇÁ·ÎÆÄÀÏÀ» È®ÀÎÇÔÀ¸·Î½á ÀÓ»óÀǴ ȯÀÚ¸¦ Ç¥Àû Ä¡·á ¹× º´¿ë¿ä¹ý¿¡ ¸Â°Ô Á¶Á¤ÇÏ°í ±¤¹üÀ§ÇÑ È­Çпä¹ý¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³·Ãß¸ç ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.

Ç¥ÀûÄ¡·á¿Í ¸é¿ªÁ¾¾çÇÐÀº TNBC Ä¡·á¸¦ ¾î¶»°Ô À籸¼ºÇϰí Àִ°¡?

»õ·Î¿î Ç¥Àû Ä¡·á¹ýÀÌ TNBC Ä¡·á¸¦ ÀçÁ¤ÀÇÇϰí ÀÖ½À´Ï´Ù. PARP ¾ïÁ¦Á¦´Â BRCA À¯ÀüÀÚ º¯À̰¡ Àִ ȯÀÚ¿¡°Ô È¿°úÀûÀÎ ¼±ÅÃÀÌ µÇ°í ÀÖÀ¸¸ç, ¸é¿ª°ü¹®¾ïÁ¦Á¦´Â PD-L1 ¾ç¼º TNBC ȯÀÚ¿¡°Ô »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ¹«ÁøÇà »ýÁ¸±â°£°ú »îÀÇ ÁúÀ» Å©°Ô °³¼±Çϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ ¹ßÀüÀº Ç×ü¾à¹°Á¢ÇÕü(ADC)ÀÇ ÃâÇöÀÔ´Ï´Ù. ADC´Â µ¶¼º ¾à¹°À» ¾Ï¼¼Æ÷¿¡ Á÷Á¢ Àü´ÞÇϰí Á¤»ó Á¶Á÷Àº º¸Á¸ÇÕ´Ï´Ù.

¶ÇÇÑ, È­Çпä¹ý¿¡ ¸é¿ª¿ä¹ýÀ̳ª Ç¥Àû Ä¡·áÁ¦¸¦ º´¿ëÇÏ´Â º´¿ë¿ä¹ýµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè¿¡¼­´Â Á¾¾çÀ¯Àüü, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º, ¾à¹°Àü´ÞÀÇ °³¹ß¿¡ ÈûÀÔ¾î Ä¡·á¹ý °£ÀÇ ½Ã³ÊÁö È¿°ú¸¦ Æò°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº TNBC Ä¡·á ¸ðµ¨À» ¹ÝÀÀÀû Ä¡·á¿¡¼­ ¿¹ÃøÀû, ¿¹¹æÀû Ä¡·á·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù.

TNBC Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµË´Ï´Ù...

TNBC Ä¡·á ½ÃÀå °³Ã´Àº À¯Àüü ÇÁ·ÎÆÄÀϸµÀÇ Áõ°¡, BRCA µ¹¿¬º¯ÀÌ °Ë»ç Áõ°¡, Ç¥Àû »ý¹°ÇÐÀû Á¦Á¦ÀÇ ÀÓ»ó °³¹ß µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÃËÁøµÉ °ÍÀÔ´Ï´Ù. ½ÃÄö½Ì ±â¼úÀÌ Àú·ÅÇÏ°í ½±°Ô ±¸ÇÒ ¼ö ÀÖ°Ô µÇ¸é¼­ ȯÀÚ ¸ÂÃãÇü Ä¡·á¸¦ À§ÇÑ È¯ÀÚ °èÃþÈ­°¡ °¡´ÉÇØÁ³½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ Çõ½Å ½Å¾à¿¡ ´ëÇÑ Á¶±â ½ÂÀÎÀº ½ÃÀå ÁøÀÔÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ¾Ï ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ, ƯÈ÷ ¸é¿ªÇ×¾Ï ºÐ¾ß¿¡ ´ëÇÑ ÅõÀÚ°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ÀϹÝÀÎÀÇ ÀÎ½Ä Á¦°í, °ËÁø È®´ë, ÀÇ·á Á¤Ã¥ÀÇ ¹ÌÃæÁ· ÀÇ·áÀε鿡 ´ëÇÑ Áö¿øÀº ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¾à¹° À¯Çü(µ¶¼Ò·çºñ½Å Á¦Á¦, »çÀÌŬ·ÎÆ÷½ºÆÄ¹Ìµå Á¦Á¦, ÆÄŬ¸®Å¹¼¿ Á¦Á¦, µµ¼¼Å¹¼¿ Á¦Á¦, Ä«º¸Çöóƾ/½Ã½ºÇÃ¶óÆ¾ Á¦Á¦, ±âŸ ¾à¹° À¯Çü), À¯Åë ä³Î(º´¿ø ¾à±¹, ¾ÏÀü¹® Ŭ¸®´Ð)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Triple Negative Breast Cancer Treatment Market to Reach US$1.4 Billion by 2030

The global market for Triple Negative Breast Cancer Treatment estimated at US$1.0 Billion in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Doxorubicin Drug, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$384.7 Million by the end of the analysis period. Growth in the Cyclophosphamide Drug segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$282.4 Million While China is Forecast to Grow at 8.4% CAGR

The Triple Negative Breast Cancer Treatment market in the U.S. is estimated at US$282.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$283.0 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Triple Negative Breast Cancer Treatment Market - Key Trends & Drivers Summarized

What Makes Triple Negative Breast Cancer So Complex and Urgent to Treat?

Triple Negative Breast Cancer (TNBC) lacks the three main receptors (estrogen, progesterone, HER2) typically targeted in standard breast cancer treatments. This receptor void makes TNBC highly aggressive, with limited treatment options, primarily centered on chemotherapy. The disease tends to occur in younger women and disproportionately affects people of African and Hispanic descent. High recurrence and metastasis rates further complicate clinical outcomes, making the pursuit of new therapeutic options a critical medical priority.

TNBC also exhibits considerable molecular heterogeneity. Researchers are uncovering diverse genetic and epigenetic subtypes, prompting a shift toward more personalized, biomarker-driven treatment approaches. By identifying distinct mutational profiles, clinicians aim to match patients with targeted or combination therapies, reducing reliance on broad-spectrum chemotherapy and minimizing side effects.

How Are Targeted Therapies and Immuno-Oncology Reshaping TNBC Treatment?

New targeted treatments are redefining TNBC therapy. PARP inhibitors have become effective options for patients with BRCA mutations, while immune checkpoint inhibitors are now being used in PD-L1 positive TNBC cases. These therapies are significantly improving progression-free survival and quality of life. Another advancement is the emergence of antibody-drug conjugates (ADCs), which deliver toxic agents directly to cancer cells, sparing healthy tissues.

Combination therapies are also on the rise, integrating chemotherapy with immunotherapy or targeted drugs. Clinical trials are evaluating synergies between modalities, supported by developments in tumor genomics, bioinformatics, and drug delivery. These innovations are moving the TNBC treatment model from reactive to predictive and preventive.

The Growth in the TNBC Treatment Market Is Driven by Several Factors…

The growth in the TNBC treatment market is driven by several factors including increasing genomic profiling, rise in BRCA mutation testing, and clinical development of targeted biologics. The affordability and accessibility of sequencing technologies are enabling patient stratification for tailored therapies. Regulatory fast-tracking of breakthrough drugs is accelerating market entry. In parallel, investment in oncology R&D is surging, especially in the immuno-oncology space. Heightened public awareness, expanded screening, and health policy support for underserved populations are further fueling market expansion.

SCOPE OF STUDY:

The report analyzes the Triple Negative Breast Cancer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Doxorubicin Drug, Cyclophosphamide Drug, Paclitaxel Drug, Docetaxel Drug, Carboplatin / Cisplatin Drug, Other Drug Types); Distribution Channel (Hospital Pharmacies, Specialty Cancer Clinics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â